Lakefront Biotherapeutics Announces Repurchase of 38,537 Shares Under Buyback Program

On June 16, 2026, Lakefront Biotherapeutics (formerly Galapagos) announced the results of its share repurchase activity conducted between June 9 and June 12, 2026. This activity was part of a buyback program initially announced on June 9, 2026. During this period, the company repurchased a total of 38,537 ordinary shares on the Euronext market (ENXT). The transactions were executed at an average price of €24.7764 per share, representing a total investment of approximately €954,809. Individual purchase prices during the window ranged from a low of €24.3600 to a high of €25.0800. Following these transactions, Lakefront Biotherapeutics holds 38,537 of its own ordinary shares as of the market close on June 12, 2026. The company continues to focus on its clinical-stage portfolio in immunology and inflammation, including its lead candidate gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases.